Favipiravir (Compound)

Synonyms:Favipiravir, 259793-96-9, 6-FLUORO-3-HYDROXYPYRAZINE-2-CARBOXAMIDE, 6-fluoro-3-oxo-3,4-dihydropyrazine-2-carboxamide, T-705, avigan, 5-fluoro-2-oxo-1H-pyrazine-3-carboxamide, Favipiravir (T-705), 6-fluoro-3-hydroxy-2-pyrazinecarboxamide, T 705, Pyrazinecarboxamide, 6-fluoro-3,4-dihydro-3-oxo-, 6-fluoro-3-hydroxy-pyrazine-2-carboxamide, Favipiravir; T-705, EW5GL2X7E0, T705, MFCD12032148, 2-Pyrazinecarboxamide, 6-fluoro-3-hydroxy-, 6-Fluoro-3,4-dihydro-3-oxo-2-pyrazinecarboxamide, Favipiravir [INN], T-705 cpd, UNII-EW5GL2X7E0, Fapilavir, Favilavir, Favipiravir [USAN:INN:JAN], Avigan (TN), FAVIPIRAVIR [MI], FAVIPIRAVIR [JAN], FAVIPIRAVIR [USAN], FAVIPIRAVIR [WHO-DD], SCHEMBL587913, Favipiravir (JAN/USAN/INN), CHEMBL221722, SCHEMBL15157866, GTPL11139, DTXSID60948878, CHEBI:134722, BCPP000056, BCP02422, EX-A2285, BBL104098, s7975, STL557913, AKOS005166863, AKOS015995178, CCG-266269, CS-0612, DB12466, PB25591, PB42412, NCGC00373041-03, NCGC00373041-06, AC-28900, DA-19682, HY-14768, MS-20791, SY110833, 6-fluoro-3-hydroxypyrazine-2-carbo xamide, AM20080851, FT-0686297, FT-0701282, A25520, D09537, 6-fluoro-3,4-dihydro-3-oxo-Pyrazinecarboxamide, EN300-1601539, A902150, J-518718, T 705,CAS;259793-96-9, Q16934561, Z1255381648
Pubchem:PUBCHEM:492405
Id:8b34b923-f2dc-5953-abfb-53387ceaf192
Description:nan

Analyze

Data Distillery
CFDE DD-Knowledge Graph

The CFDE Data Distillery Knowledge Graph contains entities and relationships across the CFDE. View Favipiravir's neighborhood in the knowledge graph.

Gene and Drug Landing Page Aggegrator
GDLPA Landing Pages Links

The Gene and Drug Landing Page Aggregator (GDLPA) finds links to primary and secondary source information from CFDE and other resources. Discover landing pages for Favipiravir.

Playbook Workflow Builder
Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with Favipiravir.

Results found

Linked to

DISPLAY PER PAGE
This repository is under review for potential modification in compliance with Administration directives.